Posted by Michael Wonder on 01 Jun 2022
FDA approval of lymphoma medicine Ukoniq (umbralisib) is withdrawn due to safety concerns
1 June 2022 - Possible increased risk of death outweighs the benefits.
Due to safety concerns, the U.S. FDA has withdrawn its approval for the cancer medicine Ukoniq (umbralisib).
